IL17A/Fi BImekizumab BKZ to Wk 24 achieved reduction in ◦ total spinal pain (SP) ◦ nocturnal SP ◦ morning stiffness (BASDAI) ◦ fatigue (FACIT-F) Deodhar et al, BE MOBILE 1,2 Abst 0409 https://t.co/vpCrG2COuB #ACR22 @RheumNow

• Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis I…

JAK and TYK-2 inhibitors and indications in SpA: ● Tofacitinib ➣ Pan JAKi (AS, PsA) ● Baricitinib ➣ JAK1,2 ● Upadacitinib ➣ JAK1 (AxSpA, PsA) ● Deucravacitinib ➣ TYK2 (PsA) Carol Langford, Year in Review #ACR22 @RheumNow https://t.co/EMLEvptySS

Differences between #uveitis pattern in AS vs. PsA and IBD 👇 This is always asked to our rheum fellows during Kelley's hour 🤓 #ACR22 @RheumNow @rheumarhyme @trishiemd @RheumaRamblings @RheumaRambolMD https://t.co/gWxQ9xdb06

Across 9 trials of Upadacitinib in RA, PsA and AS, 40%–50% of patients had ≥ 2 CV risk factors, ≥ 65 years 6%–23%. Rates of adjudicated MACE and VTE with UPA were infrequent, consistent with background rates in RA, PsA, and AS Abst 0510 https://t.co/HDkQ6ELnAy #ACR22 @RheumNow https://t.co/SRJYdFFNIQ

• MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthriti…

Abstr 0383 evaluated the use of previously developed AI algorithm to detect sacroiliitis in a new axSpA cohort. The neural network achieved -Sensitivity 82%; specificity 81% -PPV 0.89; NPV 0.70 https://t.co/PDSsiMIQUc @RheumNow #ACR22 #AI #MachineLearning #AxSpA https://t.co/mXUHUowGhQ

• Analysis of the Performance of an Artificial Intelligence Algorithm for the Det…

SELECT-AXIS 2 subgroup analysis. UPA demonstrated improved efficacy vs PBO at Wk 14 across all evaluated subgroups of pts with bDMARD-IR AS. No new safety signals. @XBaraliakos et al, Abs 0414 #ACR22 https://t.co/lTfm68XlEY https://t.co/PaWdrOljMO

• Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis wit…

Interesting data on TNFi use in ankylosing spondylitis. Early TNFi use, compared to no TNFi associated with higher CVD, stroke and MACE. @rheum_cat any thought on why? and why there were so many non-TNFi users (15k vs. 2k)? Abs#0415 @RheumNow #ACR22 https://t.co/PVkt8gPHFW

@rheum_cat et al Abs 0415 TNFi initiation early in AS dz course (compared to no initiation) showed higher risk of incident CVD, stroke & MACE individually! Residual confounding by indication cannot be excluded. Were TNFi tx pts sicker? #ACR22 @RheumNow https://t.co/ERoDhS2yOY https://t.co/8tto5AIUSP

• The Association of Early TNF Inhibitor Use with Incident Cardiovascular Events …

Can I use BASDAI to asses disease in #pregnant AS patients? Abstract #0374 #ACR22 @RheumNow; 50 women 🫃Back pain and fatigue beyond 4.5 months = not reliable 🫃BASDAI in 3rd trimester = not reliable 🫃Morning stiffness remains reliable marker of disease in pregnancy

Wanna know more about SpA in female patients? Just ask @Sineadm15! Check out my interview with her at #ACR22 @RheumNow https://t.co/NSM4pJeb6g

• Do Disease Activity Measures Really Capture AS in Women? | RheumNow

👁 What causes worse outcomes in our SpA uveitis pts? 👁 🚬 smoking Hx 🦴 ax + peripheral disease ✏️ BASDAI >4 👩‍🔬 HLA B27 +ve 🙋‍♀️ females 🧪CRP ⬆️ 👁 bilat eye involvement Abst#0373 #ACR22 @RheumNow

IL-17A/F inhibition with Bimekizumab in active nr-axSpA Wk 16 ASAS40 vs PBO • Rapid improvement 47.7 vs 21.4% • TNF naive 46.6 vs 22.9% • TNFIR 60 vs 11.8% • Wk 24 >50% ASDAS <2.1 • Improved MRI • Serious TEAE 0.4% Deodhar Abs0544 https://t.co/q9dbQP5oLD #ACR22 @RheumNow https://t.co/VCJgo56JrA

• Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients wi…